StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for AVIR yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $4.13 | $4.14 | +0.24% | 0.4M |
| 05-19 | $4.14 | $4.15 | +0.24% | 0.3M |
| 05-20 | $4.13 | $4.19 | +1.45% | 0.2M |
| 05-21 | $4.22 | $4.24 | +0.47% | 0.4M |
| 05-22 | $4.28 | $4.42 | +3.27% | 0.4M |
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2021 2021-12-31 | Q3 2021 2021-09-30 | Q2 2021 2021-06-30 | Q1 2021 2021-03-31 |
|---|---|---|---|---|
Revenue | $351.37M | $159.19M | $126.38M | $65.98M |
Operating Income | $138.38M | $17.20M | $39.34M | $30.66M |
Net Income | $121.19M | $4.06M | $1.54M | $30.71M |
EPS (Diluted) | $1.37 | $0.05 | $0.36 | $0.34 |
Total Assets | $772.89M | $843.50M | $871.54M | $840.65M |
Total Liabilities | $62.81M | $262.05M | $273.68M | $254.39M |
Cash & Equivalents | $764.38M | $839.66M | $816.46M | $833.75M |
Free Cash Flow OCF − CapEx | $-87.01M | Not available | Not available | Not available |
Shares Outstanding | 83.10M | 83.05M | 82.78M | 82.74M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.